Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.9% - Here's Why

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shot up 5.9% during trading on Wednesday . The company traded as high as $20.12 and last traded at $20.16. 59,154 shares were traded during trading, a decline of 78% from the average session volume of 270,336 shares. The stock had previously closed at $19.04.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DNTH. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Robert W. Baird cut their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, William Blair began coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $53.00.

Dianthus Therapeutics Stock Up 1.3%

The stock has a 50 day moving average of $18.59 and a 200 day moving average of $20.26. The company has a market capitalization of $662.98 million, a price-to-earnings ratio of -7.16 and a beta of 1.38.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. As a group, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. MetLife Investment Management LLC lifted its stake in Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after buying an additional 433 shares during the period. ADAR1 Capital Management LLC raised its position in shares of Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock worth $332,000 after purchasing an additional 602 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after purchasing an additional 618 shares during the period. Bank of New York Mellon Corp raised its position in shares of Dianthus Therapeutics by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after purchasing an additional 748 shares during the period. Finally, Invesco Ltd. raised its position in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after purchasing an additional 790 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.